Nautilus Biotechnology Q4 Earnings Call Highlights [Yahoo! Finance]
Nautilus Biotechnology, Inc. (NAUT)
Company Research
Source: Yahoo! Finance
of schedule to transition into active customer engagement, with Nautilus targeting pre-orders in late 2026 and instrument installations beginning in early 2027 while it starts a limited build of sales capacity (currently zero sales staff). Collaborations with the Buck Institute and Allen Institute produced novel, proteoform-level tau biology and validation, the tau proteoform assay is verified for early access sample processing by end of Q1, and an MJFF-funded $1.6M project will develop an alpha-synuclein assay for Parkinson's research. Nautilus cut operating expenses in 2025, ended Q4 with $156.1M in cash, expects 2026 cash burn of $65M–$70M with runway through 2027, and forecasts only modest services revenue (~$0.5M) in 2026 with the main instrument-driven revenue ramp beginning in 2027. Interested in Nautilus Biotechnology, Inc.? Here are five stocks we like better. Nautilus Biotechnology (NASDAQ:NAUT) used its fourth-quarter 2025 earnings call to highlight recent steps tow
Show less
Read more
Impact Snapshot
Event Time:
NAUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAUT alerts
High impacting Nautilus Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
NAUT
News
- Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of SalesGlobeNewswire
- Nautilus Biotechnology (NAUT) had its price target raised by Guggenheim from $2.50 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsGlobeNewswire
- Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026GlobeNewswire
- Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
NAUT
Earnings
- 4/29/25 - Beat
NAUT
Sec Filings
- 3/4/26 - Form SCHEDULE
- 3/4/26 - Form SCHEDULE
- 3/4/26 - Form 4
- NAUT's page on the SEC website